Systematic review and network meta-analyses of third-line treatments for metastatic colorectal cancer.
Thomas WalterNeil S HawkinsRichard F PollockFabien ColaoneSuki ShergillPaul J RossPublished in: Journal of cancer research and clinical oncology (2020)
Regorafenib, TAS-102 and SIRT using Y-90 resin microspheres are more effective than BSC in third-line treatment of mCRC; however, study heterogeneity made comparisons between active treatments challenging. SIRT is a viable treatment for third-line mCRC and its favorable AE profile should be considered in the therapeutic decision-making process.